Safety and Efficacy of Cimicoxib, a Selective COX-2 Inhibitor, in Combination With Sertraline Compared to Sertraline Combined With Placebo in Treatment of Major Depression.

Trial Profile

Safety and Efficacy of Cimicoxib, a Selective COX-2 Inhibitor, in Combination With Sertraline Compared to Sertraline Combined With Placebo in Treatment of Major Depression.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 May 2014

At a glance

  • Drugs Cimicoxib (Primary) ; Sertraline
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms SECIM
  • Sponsors Affectis Pharmaceuticals
  • Most Recent Events

    • 25 May 2010 Actual patient number (169) added as reported by ClinicalTrials.gov.
    • 25 May 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 25 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top